Weight-Loss Drugs Boost Women's Employment, Study Finds

A recent study published this week suggests that the increasing use of weight-loss drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has a notable economic impact on women's employment. The research, which analyzed anonymized health and employment data from over 100,000 individuals in the United States between 2020 and 2023, found that women who started taking these medications were 15% more likely to enter the workforce or secure full-time employment within six months compared to a control group. This increase is attributed to improved health outcomes and increased energy levels, enabling greater participation in the labor market.

Conversely, the study also observed a correlation between men's use of these weight-loss drugs and changes in their relationship status. Men who began using the medications showed a 10% higher likelihood of experiencing a breakup or divorce within the same six-month period. Researchers hypothesize this could be linked to shifts in relationship dynamics, potentially influenced by changes in physical appearance or the partners' perceptions. The study did not specify whether the weight-loss drugs were prescribed for diabetes or obesity.

The economic implications extend beyond individual employment. The increased labor force participation among women could contribute to higher household incomes and potentially boost consumer spending. However, the study also highlights potential societal shifts related to relationship stability and the broader impact of pharmaceutical interventions on personal and economic lives. The research was conducted by economists at the University of Chicago and funded by a grant from the National Bureau of Economic Research.